Latest stories on ABBV
AbbVie: Still Strong Growth, But Patent Cliff Getting Closer
Seeking Alpha58 · neutralgeneral
AbbVie: Analyzing Performance, Pipeline, And Pricing Ahead Of Q3 (Strong Buy)
Seeking Alpha64 · neutralanalyst
AbbVie Files FDA BLA for Etentamig in Multiple Myeloma, Ticker ABBV
GuruFocus58 · neutralproduct/pr
AbbVie submits etentamig BLA for multiple myeloma
Seeking Alpha63 · neutralproduct/pr
AbbVie submits BLA for etentamig to U.S. FDA
The Fly63 · neutralproduct/pr
AbbVie Options Price In a Sudden 5% Swing—What Investors Must Know Before Oct. 30
24/7 Wall St.52 · neutralearnings
Billionaire Ken Griffin Is Buying This Dividend King That Wall Street Still Rates a Buy
The Motley Fool63 · neutralanalyst
Stocktwits Pharma Pulse: Big Pharma Earnings, Cancer Updates And 2 FDA Deadlines — The Week’s Biotech Watchlist
Stocktwits News55 · neutralearnings
A Worthwhile Exit Strategy
ETF Trends44 · neutralgeneral
FDA approves subcutaneous induction regimen for AbbVie’s Skyrizi for Crohn’s
The Fly74 · bullishproduct/pr
AbbVie’s Dividend Survived Humira’s Patent Cliff. Will Merck and Amgen’s?
24/7 Wall St.52 · neutralgeneral
AbbVie shares may move 5% on Oct. 30 earnings release
Investing.com Markets50 · neutralearnings
Avalo Therapeutics downgraded to Neutral at Guggenheim after AbbVie data
The Fly38 · neutralanalyst
AbbVie price target raised to $294 from $258 at Goldman Sachs
The Fly64 · neutralanalyst
3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach
MarketBeat58 · neutralgeneral
What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizer
The Motley Fool44 · neutralmacro
Great News for AbbVie Stock Investors
The Motley Fool58 · neutralgeneral
AbbVie Targets Essential Tremor With New Mid-Stage Trial, Adding Depth to Its Neurology Pipeline
TipRanks58 · neutralproduct/pr
AbbVie Phase 3 Intrepid trial data ‘underwhelms,’ says RBC Capital
The Fly34 · bearishanalyst
AbbVie sees positive late-stage results for lutikizumab in hidradenitis suppurativa
Seeking Alpha64 · neutralproduct/pr
AbbVie’s Phase 3 INTREPID trial posts a 31.4% HiSCR75 response at Week 16 for lutikizumab in hidradenitis suppurativa
October 22, 2026
MarketChameleon74 · bullishproduct/pr
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
Reuters64 · neutralproduct/pr